Earlier, an in vitro study by the team of zhongnan shan found that the compound plate blue root was effective for the new coronary virus, as well as the video was hotly distributed online, prompting consumers in various markets to buy the plate blue root, as well as large increases in the price and market value of baek yunshan (600332. Sh) shares。
Zhongnanshan's response: someone took it out of context
On 23 october, the recipient of the order of the republic and a member of the chinese academy of engineering, zhongnanshan, responded that his words had been taken out of context and “expanded”. Zhongnanshan stated: “i said a few days ago in the tripartite cooperation agreement (forum) in the bay of australasia that the combination of plate blue root, rather than plate blue root, had an anti-container virus in the laboratory, was far from effective in the body, and that the white cloud mountain pharmaceutical plant, as an `inline pedestrian', should be well understood, but (where) i was taken out of context to expand my sentence, even to the ground floor, which was a distortion and clarified by the authorities.”
Cvm: if violations are found, they are investigated and prosecuted in accordance with the law
On 23 october, the cvm press spokesman, golly, stated at the cvm press conference that the cvm had taken note of some of the media reports on the findings of an in vitro study of the plagued blue roots of the white cloud mountain. The company issued a clarification bulletin on 19 october and made a risk alert。
According to the bulletin, the relevant findings in the media report are only the results of an experiment against the in vitro screening of new coronary virus particles in combination with the joint venture white cloud hill and yellow (50 per cent of the joint venture held in shares, not covered by the merger), which will require further work on the product, with some uncertainty。
The cvm will follow the situation on an ongoing basis and will investigate and prosecute violations if they are detected。
Source: china securities journal, china economics and finance
